[ Syntimmune raises $50M in Series B ]
Syntimmune has raised $50 million in Series B funding.
Founded in 2013, Syntimmune is a biotechnology company that focuses on FcRn biology for the treatment of IgG-mediated autoimmune diseases.
Thenew financing will further advance Syntimmune’s clinical development program, which includes two ongoing Phase 1b/2a clinical trials of the company’s lead drug candidate, SYNT001, in pemphigus and warm autoimmune hemolytic anemia, support further preclinical development of SYNT002, as well as additional research activities.
|City||New York, NY|
|Founder / CEO||David de Graaf|
|Investors||Partners Innovation Fund|
|Apple Tree Partners|
|Previous Investors||same as above|